Gilead Sciences reported its fourth quarter 2024 earnings, exceeding analysts' expectations with an adjusted earnings per share (EPS) of $1.90, compared to the consensus estimate of $1.70. The company's revenue for the quarter reached $7.57 billion, surpassing the expected $7.14 billion, marking a 6% increase year-over-year. This growth was primarily driven by strong sales in its HIV and Oncology segments, which helped offset a significant decline in Veklury (remdesivir) sales, which fell 53% to $337 million. Looking ahead, Gilead projects its adjusted EPS for fiscal year 2025 to be between $7.70 and $8.10, above the consensus estimate of $7.58. Additionally, the company anticipates product sales for 2025 to be in the range of $28.2 billion to $28.6 billion, compared to the estimate of $28.42 billion. Gilead's stock rose approximately 5% in after-hours trading following the announcement of these results.